FCRL5 Antibody

What is FCRL5 and why is it significant in immunological research?

FCRL5, also known as FcRH5, CD307, CD307e, IRTA2, or BXMAS1, is a 120 kDa transmembrane protein with sequence homology to classical Fc receptors. It's structurally characterized by having nine immunoglobulin-like domains in its extracellular portion (in humans), a 21 amino acid transmembrane segment, and a 105 amino acid cytoplasmic domain containing both immunotyrosine activation motifs (ITAMs) and immunotyrosine inhibitory motifs (ITIMs) .

FCRL5's significance stems from its restricted expression pattern on mature B lineage cells in lymphoid tissues and blood, making it an excellent B-cell lineage marker. Additionally, it plays crucial roles in:

• B cell receptor (BCR) signaling regulation

• B cell proliferation and activation (both promotion and inhibition)

• Potential B cell development and differentiation in peripheral lymphoid organs

• Immunoregulation in marginal zone B-cells

Its unique binary modulatory effects on antigen receptor signaling and its differential expression in various B cell malignancies make it a valuable research target for both basic immunology and clinical applications.

How do human and mouse FCRL5 differ, and what implications does this have for research?

The key differences between human and mouse FCRL5 include:

These differences have important implications for research:

• Mouse models may not fully recapitulate human FCRL5 biology due to structural differences

• Antibodies developed against human FCRL5 may not cross-react with mouse FCRL5

• Binding studies in mice may yield different results than in humans

• Transgenic models expressing human FCRL5 may be necessary for certain therapeutic studies

When designing experiments, researchers should carefully consider these species differences, especially when translating findings from animal models to human applications.

What are the optimal methods for using FCRL5 antibodies in flow cytometry?

Flow cytometry represents one of the most common applications for FCRL5 antibodies. For optimal results:

Sample preparation:

• Use fresh cells when possible, as FCRL5 expression may decrease with extended culture

• For peripheral blood samples, use whole blood lysis methods or isolated lymphocyte preparations

• For tissue samples, ensure gentle mechanical dissociation to preserve membrane proteins

Antibody selection and staining:

• Choose antibodies validated specifically for flow cytometry (e.g., BD Biosciences RY586 Mouse Anti-Human FCRL5)

• Consider fluorochrome brightness based on expected expression levels (FCRL5 can have variable expression)

• Use appropriate blocking (Fc block) to prevent non-specific binding

• Include proper compensation controls if using multiple fluorochromes

• Include FMO (fluorescence minus one) controls to accurately identify positive populations

Gating strategy:

• First gate on lymphocytes/B cells using standard markers (CD19+, CD20+)

• Then analyze FCRL5 expression within these populations

• Consider using additional markers to identify specific B cell subsets of interest

Common pitfalls to avoid:

• Avoid harsh fixation protocols that may alter epitope recognition

• Be aware that FCRL5 expression varies across B cell development stages

• Remember that Epstein-Barr virus transformation can upregulate FCRL5 expression, potentially confounding results in transformed cell lines

How can researchers effectively use FCRL5 antibodies in immunohistochemistry/immunofluorescence studies?

While less common than flow cytometry, IHC/IF studies with FCRL5 antibodies can provide valuable spatial information:

Tissue preparation considerations:

• For FFPE tissues, optimize antigen retrieval methods (typically heat-induced epitope retrieval in citrate buffer pH 6.0)

• For frozen sections, mild fixation (2-4% PFA) typically preserves FCRL5 epitopes

• Consider section thickness (5-8 μm is typically optimal)

Protocol optimization:

• Test multiple antibody clones as epitope accessibility may vary by tissue preparation method

• Optimize antibody concentration through titration experiments (typically 1-10 μg/ml range)

• Include proper blocking steps to reduce background (normal serum matching secondary antibody species)

• For IF studies, consider photobleaching properties of chosen fluorophores

Controls to include:

• Positive controls: tissues known to express FCRL5 (lymphoid tissues, specific B cell malignancies)

• Negative controls: tissues lacking B cells, isotype controls, and secondary-only controls

• For dual staining, include single-stained controls to assess antibody cross-reactivity

Analysis approaches:

• Quantify FCRL5 expression using digital image analysis when possible

• Co-stain with markers of different B cell subpopulations for contextual information

• Consider comparing FCRL5 with other Fc receptor family members for differential expression patterns

How is FCRL5 involved in autoimmune disease pathogenesis?

Recent research has revealed a significant role for FCRL5 in autoimmune pathology:

Mechanism of FCRL5 in breaking B cell anergy:
B cell anergy—a state of functional unresponsiveness—is crucial for maintaining self-tolerance and preventing autoimmunity. Studies using Fcrl5 transgenic mice have demonstrated that upregulated Fcrl5 expression disrupts this B cell anergy mechanism, contributing to autoimmune pathogenesis.

The experimental evidence includes:

• Fcrl5 transgenic mice developed systemic autoimmunity with age

• In the MD4/ML5 model system of B cell anergy, Fcrl5 overexpression restored levels of HEL-specific antibodies, indicating a break in anergy

• B cells from MD4/ML5/Fcrl5 transgenic mice showed higher cell surface IgM levels and enhanced proliferation in response to self-antigen

• These B cells efficiently upregulated activation markers (CD69, CD86, MHC-II, PD-L1) upon stimulation

Role in TLR signaling and autoimmunity:
FCRL5 appears to modulate TLR signaling, with multiple consequences:

• Co-stimulation with CpG (TLR9 ligand) and Fcrl5 resulted in increased B cell activation

• TLR7-stimulated CD80 expression was promoted by Fcrl5 co-stimulation

• In imiquimod-induced lupus models, Fcrl5 transgenic mice showed increased autoantibody production and kidney pathology

• Fcrl5 overexpression led to expansion of age/autoimmunity-associated B cells (ABCs), a key autoreactive subset

These findings suggest FCRL5 as a potential therapeutic target for autoimmune diseases, particularly those mediated by B cell hyperactivity.

What is the current status of FCRL5-targeted therapies in multiple myeloma?

FCRL5 has emerged as a promising target for multiple myeloma (MM) therapy, with several approaches under investigation:

CAR-T cell therapy targeting FCRL5:

• FCRL5 is consistently expressed on malignant plasma cells, even when BCMA expression diminishes following BCMA-targeted therapies

• FCRL5-directed CAR-T cells have shown efficacy in both in vitro co-culture with MM cell lines and in vivo using cell-derived xenograft mouse models

• A first-in-human case report demonstrated that FCRL5-directed CAR-T cells exhibited antitumor activity against extramedullary MM after progression of both BCMA- and GPRC5D-targeted CAR-T therapies

• The patient achieved complete response by month 4 after FCRL5-targeted CAR-T treatment, with manageable short-term adverse effects

Expression patterns supporting FCRL5 as a therapeutic target:

• Among MM cell lines evaluated (U266, NCI-H929, MM1.S, KMS11, ARD, RPMI-8226), NCI-H929 cells showed the highest FCRL5 expression

• FCRL5 is overexpressed on malignant B cells in multiple myeloma

• The FCRL5 gene maps to the 1q21 chromosomal locus, a common site of rearrangements in B cell malignancies

• Elevated levels of soluble FCRL5 are found in the serum of many B cell leukemia patients

This evidence collectively indicates that FCRL5-directed therapies may provide a valuable alternative for MM patients, particularly those who have relapsed after other targeted therapies.

How does IgG binding to FCRL5 differ from binding to classical Fc receptors?

FCRL5 exhibits a unique and complex binding mechanism with IgG that distinguishes it from classical Fc receptors:

Binding characteristics:

• FCRL5 binds different IgG isotypes with varying affinities: IgG1 and IgG4 with ~1 μM KD, while IgG3 binding is approximately ten times weaker

• IgG2 samples display a wide range of affinities, indicating that factors beyond isotype affect binding

• The interaction consists of two kinetic components, suggesting a complex binding mechanism

• Only glycosylated IgG containing both Fab arms and the Fc region binds with high affinity

• The sialic acid content of the IgG carbohydrate alters FCRL5 binding

Structural requirements for binding:

• Both IgG-Fc and IgG-F(ab')2 fragments can bind FCRL5 independently but with low affinity

• This reveals a two-step binding mechanism for whole IgG, distinct from classical Fc receptors

• Domains 1 and 3 of FCRL5, as well as epitopes at domain boundaries (1/2 and 2/3), are critical for IgG binding

Functional implications:
This distinctive binding mechanism suggests FCRL5 may function as a quality control receptor, enabling B cells to sense the integrity and quality of IgG molecules. Recognition of undamaged IgG could allow B cells to engage recently produced antibodies, potentially providing feedback on antibody production or function.

This complex binding mechanism highlights the need for specialized experimental approaches when studying FCRL5-IgG interactions, including surface plasmon resonance methods that can detect multiple binding components .

What experimental approaches can best elucidate the dual modulatory functions of FCRL5?

FCRL5 possesses a unique binary regulatory capacity through its ITAM and ITIM signaling motifs. The following experimental approaches can help elucidate this dual functionality:

In vitro signaling studies:

• Co-immunoprecipitation assays to identify binding partners of FCRL5's phosphorylated ITAM and ITIM motifs

• Phospho-specific antibodies to track activation states of key signaling molecules

• Calcium flux assays to measure immediate signaling consequences

• Site-directed mutagenesis of individual ITAM and ITIM motifs to dissect their specific contributions

• Proximity ligation assays to detect protein-protein interactions in situ

B cell subset-specific analyses:
Research has shown that FCRL5's regulatory effects differ between B cell subsets. To investigate this:

• Isolate distinct B cell populations (marginal zone vs. B1 B cells) for comparative analyses

• Measure basal phosphatase and kinase activities (particularly SHP-1 and Lyn)

• Compare BCR responsiveness between subsets with and without FCRL5 stimulation

• Analyze how FCRL5 engagement differentially affects downstream signaling pathways

Complex co-receptor studies:

• Investigate FCRL5's interaction with other co-receptors, particularly CD21

• Assess how co-engagement of FCRL5 with CR2 and BCR affects calcium responses

• Examine potential differential effects on signaling cascades via phospho-flow cytometry

• Use super-resolution microscopy to visualize receptor clustering and co-localization

Data from these approaches shows:
FCRL5's binary regulation directly correlates with SHP-1 and Lyn activity, which differs between marginal zone and B1 B cells. When associated with the BCR, FCRL5's ITAM-like and ITIM sequences become tyrosine phosphorylated and recruit Lyn Src-family kinase and SHP-1 protein tyrosine phosphatase, providing non-redundant contributions to FCRL5's counterregulatory function .

What methodological considerations are important when analyzing FCRL5 expression in clinical samples?

Clinical analysis of FCRL5 expression presents several methodological challenges that researchers should address:

Sample handling considerations:

• Process samples rapidly as FCRL5 expression may be altered during extended storage

• Standardize preservation methods (fixatives, freezing protocols) to maintain epitope integrity

• For serum/plasma analysis of soluble FCRL5, use consistent collection tubes and processing times

• Document relevant patient information including treatments that might affect B cell populations

Expression heterogeneity assessment:

• Be aware that FCRL5 expression varies across different B cell malignancies

• Multiple myeloma samples typically show higher FCRL5 expression than cell lines

• Expression can change following treatment, particularly with B cell-targeting therapies

• Consider analyzing both membrane-bound and soluble forms of FCRL5

Quantification methods:

• For flow cytometry, use antibody-binding capacity (ABC) beads to standardize expression levels

• For immunohistochemistry, implement digital image analysis with standardized scoring systems

• For mRNA analysis, select appropriate reference genes for normalization

• When possible, correlate protein and mRNA expression data

Antibody selection guidelines:

• Choose antibodies with demonstrated specificity for clinical applications

• Consider using multiple antibody clones that recognize different FCRL5 epitopes

• Validate antibodies on appropriate positive and negative control samples

• For clinical studies, use antibodies with established clinical validation when available

Data interpretation table for FCRL5 expression:

These methodological considerations ensure more reliable and clinically relevant FCRL5 expression data.

How might FCRL5 antibodies be utilized in combined targeting approaches for resistant B cell malignancies?

Recent clinical evidence suggests promising directions for FCRL5-based combination therapies:

Sequential or combinatorial CAR-T approaches:

• FCRL5 expression persists even when BCMA expression diminishes following BCMA-targeted CAR-T therapy

• A first-in-human case demonstrated that FCRL5-directed CAR-T cells could achieve complete response in a patient who had progressed after both BCMA- and GPRC5D-targeted therapies

• This suggests potential sequential targeting strategies using different B cell antigens to overcome resistance

• Emerging research is exploring dual-targeting CAR constructs that simultaneously recognize FCRL5 and other B cell antigens

Antibody-drug conjugate (ADC) approaches:

• FCRL5-targeted antibody-drug conjugates have shown effectiveness in treating multiple myeloma

• These could be used in combination with other targeted therapies or as preparative regimens before CAR-T therapy

• The restricted expression of FCRL5 to B lineage cells makes it an attractive ADC target with potentially limited off-target toxicity

Enhanced CAR-T engineering:

• FCRL5 CAR-T cells that secrete IL-15 have been engineered to enhance persistence

• These showed higher CD8+ T-cell ratios and elevated CD28 expression post-transfection

• Such approaches might overcome limitations of current CAR-T therapies related to T cell persistence

• Combining FCRL5 targeting with immune checkpoint inhibition (e.g., PD-1 antibodies) has shown promise in enhancing CAR-T expansion

These combination approaches represent promising directions for overcoming treatment resistance in B cell malignancies, particularly multiple myeloma.

What are the key technical challenges in developing highly specific FCRL5 antibodies for research and clinical applications?

Developing highly specific FCRL5 antibodies presents several technical challenges:

Epitope selection considerations:

• FCRL5 contains multiple immunoglobulin-like domains with different functional roles

• Domains 1 and 3, as well as the domain boundaries (1/2 and 2/3), are critical for IgG binding

• Antibodies targeting different epitopes may have distinct functional effects on FCRL5 activity

• The presence of alternative splice variants with differing domain compositions complicates epitope selection

Cross-reactivity concerns:

• FCRL5 shares homology with other FCRL family members

• Careful screening against FCRL1-4 and FCRL6 is necessary to ensure specificity

• Species cross-reactivity is limited due to the 49% sequence identity between human and mouse FCRL5

• Different glycosylation patterns may affect antibody recognition

Validation requirements:
For research antibodies:

• Validation should include multiple cell lines with varying FCRL5 expression levels

• Knockout/knockdown controls are valuable for confirming specificity

• Testing on primary cells is essential due to potential differences from cell lines

• Multiple application validations (flow, IHC, WB, etc.) require different optimization approaches

For clinical antibodies:

• More stringent specificity testing with extensive cross-reactivity panels

• Stability testing under various storage and handling conditions

• Consistent lot-to-lot performance with minimal variation

• Binding kinetics characterization to ensure predictable in vivo behavior

Research finding: A study using a panel of 19 anti-FCRL5 mAbs with defined reactivity identified that six mAbs blocked IgG binding, indicating the complexity of FCRL5's interaction surfaces and the importance of epitope mapping in antibody development .

Understanding these challenges and implementing rigorous development and validation protocols is essential for producing FCRL5 antibodies suitable for advanced research and clinical applications.